Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer

Naiyer A, Rizvi,MD
Published Online: Sunday, November 10, 2013

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Rizvi says the anti-PD-1 antibodies nivolumab and MK-3475, and the anti-PD-L1 antibody MPDL3280A, are all being developed as treatments for stage IV lung cancer. Early studies of these agents have shown a response rate in the 20% range in patients with heavily pre-treated lung cancer who are resistant to chemotherapy and have failed all standard therapies. Rizvi says a 20% response rate is very encouraging for this group of patients.

Many of these patients have also showed durable responses, Rizvi says. Recently, the data from the nivolumab trial were updated to show a 2-year survival of 24%, which Rizvi says is a very high number for that patient population.

<<< View coverage from the New York Lung Cancer Symposium

Online CME Activities
Free CME from PER
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
Updates in Supportive Care From ASCO 2014
Cancer Summaries and Commentaries: Update from Chicago – Advanced Gastrointestinal Cancers
Cancer Summaries and Commentaries: Update from Chicago – Skin Cancer and Other Cutaneous Malignancies
More Reading
Publications
$auto_registration$